Passa al contenuto
Merck
  • Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.

The Journal of pharmacology and experimental therapeutics (2016-12-15)
J Di Salvo, H Nagabukuro, L A Wickham, C Abbadie, J A DeMartino, A Fitzmaurice, L Gichuru, A Kulick, M J Donnelly, N Jochnowitz, A L Hurley, A Pereira, A Sanfiz, G Veronin, K Villa, J Woods, B Zamlynny, E Zycband, G M Salituro, T Frenkl, A E Weber, S D Edmondson, M Struthers
ABSTRACT

Although the physiologic role of muscarinic receptors in bladder function and the therapeutic efficacy of muscarinic antagonists for the treatment of overactive bladder are well established, the role of β

MATERIALI
Numero di prodotto
Marchio
Descrizione del prodotto

Sigma-Aldrich
CL 316,243 hydrate, ≥98% (HPLC), powder
Sigma-Aldrich
Kit e reagenti per trigliceridi e glicerolo libero, 1 kit sufficient for 1000 reactions
Sigma-Aldrich
Darifenacin hydrobromide, ≥98% (HPLC)
Sigma-Aldrich
Methoctramine hydrate, ≥97% (NMR), solid